Nutranomics Receives Initial Purchase Order for New Testosterone Booster Formula from Japanese Nutritional Supplement Company
DRAPER, Utah, Dec. 4, 2013 /PRNewswire/ -- Nutranomics, Inc. (OTCBB: NNRX) (OTCQB: NNRX) ("Nutranomics" or the "Company") is pleased to report that it has received a purchase order for 500,000 capsules of a natural testosterone booster formula recently developed by Nutranomics. The initial purchase order is the result of a successful custom product development request made several months ago by a confidential Japanese nutritional supplement company.
"In just three months, our team successfully utilized its extensive product development skills to custom create this natural testosterone booster formula and secure an initial purchase order from a first-time Japanese client," stated Nutranomics CEO, Dr. Tracy K. Gibbs. "Although the initial purchase order for $24,000 is not substantially large, once again, this shows that our current Asian markets expansion strategy has been successful at generating new business from entirely new client channels. We anticipate developing other custom formulated products for this client in the future and potentially securing recurring purchase orders."
Dr. Gibbs concluded, "I look forward to exploring other possible distribution and private label opportunities for the Nutranomics testosterone booster formula in other markets."
About Nutranomics
Nutranomics is a publicly traded company engaged in research and development of nutritional food products. In 1997, Nutranomics produced and branded its own product line, and began to sell to the retail outlets and to the public. Nutranomics has also produced formulas for hundreds of other companies. Nutranomics' mission is to increase human health and longevity through education and self-awareness. The Company has sales representatives throughout North America and Asia.
For further information regarding Nutranomics, Inc., please contact our investor relations representatives at [email protected] or call toll-free (888) 616-3999.
Notice Regarding Forward-Looking Statements
This news release contains "forward-looking statements." Statements in this press release that are not purely historical are forward-looking statements and include any statements regarding beliefs, plans, expectations or intentions regarding the future. Such forward-looking statements include, but are not limited to, the Company's ability to develop additional products for the Japanese client and securing future purchase orders. Actual results could differ from those projected in any forward-looking statements due to numerous factors. Such factors include, among others, the inherent uncertainties associated with developing new products and operating as a development stage company, our ability to raise the additional funding we will need to continue to pursue our business and product development plans, competition in the industry in which we operate and market conditions. These forward-looking statements are made as of the date of this news release, and we assume no obligation to update the forward-looking statements, or to update the reasons why actual results could differ from those projected in the forward-looking statements, except as required by applicable law, including the securities laws of the United States. Although we believe that any beliefs, plans, expectations and intentions contained in this press release are reasonable, there can be no assurance that any such beliefs, plans, expectations or intentions will prove to be accurate. Investors should consult all of the information set forth herein and should also refer to the risk factors disclosure outlined in the reports and other documents we file with the SEC, available at www.sec.gov. These statements have not been evaluated by the Food and Drug Administration. These products are not intended to diagnose, treat, cure or prevent any disease.
SOURCE Nutranomics, Inc.
WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM?
Newsrooms &
Influencers
Digital Media
Outlets
Journalists
Opted In
Share this article